Progenics Pharmaceuticals (Progenics Pharmaceuticals) Total Inventories : $0.00 Mil (As of Mar. 2020)

View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals Total Inventories?

Progenics Pharmaceuticals's total inventories for the quarter that ended in Mar. 2020 was $0.00 Mil. Progenics Pharmaceuticals's average total inventories from the quarter that ended in Dec. 2019 to the quarter that ended in Mar. 2020 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Progenics Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Mar. 2020 was $-0.39.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Progenics Pharmaceuticals's Days Inventory for the three months ended in Mar. 2020 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Progenics Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2020 was 0.00.

Progenics Pharmaceuticals Total Inventories Historical Data

The historical data trend for Progenics Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals Total Inventories Chart

Progenics Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Total Inventories

Get a 7-Day Free Trial

Progenics Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

Progenics Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Progenics Pharmaceuticals (NAS:PGNX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Progenics Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2020 is

	Net-Net Working Capital Per Share (Q: Mar. 2020 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(29.531	+	0.75 * 6.19	+	0.5 * 0	-	67.731
-	0	-	0)	/	86.596
=	-0.39

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Progenics Pharmaceuticals's Days Inventory for the three months ended in Mar. 2020 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2020 )	/	Cost of Goods Sold (Q: Mar. 2020 )	*	Days in Period
	=	0	/	1.558	*	365 / 4
	=	0.00

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Progenics Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2020 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2020 )	/	Average Total Inventories (Q: Mar. 2020 )
	=	1.558	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Progenics Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2020 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2020 )	/	Revenue (Q: Mar. 2020 )
	=	0	/	6.248
	=	0.00

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Progenics Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Progenics Pharmaceuticals (Progenics Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (NAS:PGNX) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007

Website

http://www.progenics.com

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Executives

Asha Das	officer: Chief Medical Officer	C/O PROGENICS PHARMACEUTICALS, INC., 1 WORLD TRADE CENTER, 47TH FL, SUITE J, NEW YORK NY 10007
Ann L. Macdougall	director	C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Karen Jean Ferrante	director	150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Heinz Christoph Maeusli	director	SCHUETZENWEG 3, ENGELBURG V8 9032
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Bradley L Campbell	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Balaji Venkataraman	10 percent owner, other: See Explanation of Responses	FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Virinder Nohria	10 percent owner, other: See Explanation of Responses	1055 POWERS PLACE, SUITE B, ALPHARETTA GA 30009
Nicole Williams	director
David A Scheinberg	director	325 CENTRAL PARK W, APT 38, NEW YORK NY 10025
Michael D Kishbauch	director	18 CHERRYVILLE RD, FLEMINGTON NJ 08822
Broadfin Healthcare Master Fund Ltd	10 percent owner	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler	10 percent owner	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc	10 percent owner	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022